Home Print this page Email this page Small font size Default font size Increase font size
Users Online: 343
Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Contacts Login 
Year : 2014  |  Volume : 28  |  Issue : 2  |  Page : 86-92

A prospective study of comparison of efficacy and safety between levocetirizine and olopatadine in chronic idiopathic urticaria

1 Department of Pharmacology, NIMS Medical College, Jaipur, India
2 Department of Pharmacology, J.L.N. Medical College, Ajmer, India
3 Department of Pharmacology, S.M.S. Medical College, Jaipur, Rajasthan, India
4 Department of Dermatology, S.M.S. Medical College, Jaipur, Rajasthan, India

Correspondence Address:
Dhirendra Kumar Mahawar
V.P.-Mohanpura, Tehsil-Bassi, Jaipur - 303 301, Rajasthan
Login to access the Email id

Source of Support: J. L. N. Medical College and Associated Hospital, Ajmer, Rajasthan, India, Conflict of Interest: None

DOI: 10.4103/0972-6691.140783

Rights and Permissions

Aims and Objective: The aim was to compare efficacy and safety of olopatadine with levocetirizine in patients of chronic idiopathic urticaria (CIU). Materials and Methods: This was a prospective, open, parallel, comparative randomized study. After assessing inclusion and exclusion criteria, patients were randomized and divided into two treatment groups: Group A (n = 77) received levocetirizine 5 mg once a day orally, and Group B (n = 77) received olopatadine 5 mg twice a day orally for 6 weeks. Patients were evaluated in terms of parameters under study that is, urticarial activity score (UAS), dermatological life quality index (DLQI), visual analog scale (VAS) (daytime sedation), and adverse drug reactions monitoring at every (2 weeks) visit. Statistical Analysis: We used the Student's t-test and the analysis of covariance for comparison of the results and the Chi-square test for comparison of incidence of adverse effects . Results: Both drugs reduced UAS significantly (P < 0.05) at all visits and olopatadine reduced UAS more than levocetirizine at 2 weeks (P < 0.05). Both drugs altered VAS at all visits significantly; however, inter-group differences were not significant. Each drug reduced DLQI score significantly. Levocetirizine reduced more DLQI than olopatadine, but the difference was not significant (P > 0.05). Olopatadine was associated with more side-effect profile, and most common side-effect was somnolence in both groups. Conclusion: Levocetirizine is a marginally superior drug as compared with olopatadine for long-term treatment of CIU in Indian population.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded284    
    Comments [Add]    
    Cited by others 2    

Recommend this journal